71 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:29am
consist primarily of rebates and return reserves, as well as provisions for litigation and restructuring. 1) Rebates and Return Reserves Takeda has … such as the U.S. Medicaid Drug Rebate Program, the U.S. Medicare Part-D Rebate Program and the U.S. Commercial Managed Care Program. 2) Provisions for Litigation
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:24am
). The increase was primarily driven by increases of restructuring expenses, additional losses recorded for the supply agreement litigation with AbbVie, Inc … as an increase in financial expenses in the fiscal year ended March 31, 2024 due to factors including interest recorded for the supply agreement litigation
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
9 May 24
Current report (foreign)
6:01am
to earnings mix
Free cash flow
400.0 to 500.0
Mainly litigation payment and higher than anticipated working capital
CAPEX (cash flow base)
(480.0 … on historical trends
Other operating income
Other operating expenses
FY2023 includes litigation expense and revaluation of contingent consideration
6-K
TAK
Takeda Pharmaceutical Co
9 May 24
Current report (foreign)
6:01am
by increases of restructuring expenses, additional losses recorded for the supply agreement litigation with AbbVie, Inc. ("AbbVie") in the fiscal year … ended March 31, 2024 due to factors including interest recorded for the supply agreement litigation with AbbVie and increased expense on hyperinflation
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
and additional losses recorded for the supply agreement litigation with AbbVie, Inc. (AbbVie) in the current period, partially offset by a decrease … the restructuring expenses JPY 60,130 million, additional losses recorded for the supply agreement litigation with AbbVie, Inc. (AbbVie) in the current
6-K
e2d4e2 vrsz
1 Feb 24
Current report (foreign)
6:06am
6-K
EX-99.1
qkkd497 2bbrx
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
c5dx12 gb
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
8rt lxdn0h1r1
30 May 23
Current report (foreign)
6:11am
6-K
mk1t8l8
31 May 22
Current report (foreign)
6:20am
6-K
EX-99.1
uo9n45pd20y06nx
31 May 22
Current report (foreign)
6:07am
6-K
EX-99.1
qf5ba18gu85vm8
31 May 22
Current report (foreign)
12:00am
6-K
l9eed6
10 Feb 22
Current report (foreign)
6:03am
6-K
EX-99.1
pfumoz03skn5f0lcyx2
11 Jan 22
Current report (foreign)
6:02am
6-K
hi2v5bd1xkujxhvc50se
5 Nov 21
Current report (foreign)
6:02am
6-K
qcy29 1zckkk
6 Aug 21
Current report (foreign)
6:06am